DKSH partners with BridgeBio to distribute ATTR-CM transthyretin stabilizer in Asia-Pacific markets

BridgeBio Pharma

BBIO

0.00

DKSH entered a strategic distribution partnership with BridgeBio to commercialize a transthyretin stabilizer for ATTR-CM in selected Asia-Pacific markets.
DKSH will handle distribution and commercialization in Australia, Singapore, South Korea, Taiwan, subject to regulatory approvals.
The product targets cardiomyopathy from wild-type or variant transthyretin-mediated amyloidosis in adults, aiming to cut cardiovascular deaths, hospitalizations.
DKSH will support regulatory, medical affairs, market access, launch execution using its regional commercialization platform and distribution infrastructure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DKSH Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2342780_en) on June 11, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.